$NRIX

Nurix Therapeutics (NRIX) shares rose 3.4% after appointing Dr. Arati V. Rao as chief medical officer. Dr. Rao will oversee clinical development, including the BTK degrader bexobrutideg partnered with Roche. The stock closed at $16.33, up 2.8% from the previous close. Nurix has faced volatility, including a 39.8% drop last week due to Sanofi ending a Phase 1 study. The company has $1.1B in cash, funding operations into 2029.

Nurix Therapeutics (NRIX) shares dropped 38% in after-hours trading on Tuesday after Sanofi (SAN) decided to halt the Phase I trial of SAR448272, an oral STAT6 degrader. Sanofi notified Nurix of the decision to discontinue the clinical trial.

ARK Invest sold $12.8 million in Alphabet shares on Nov. 4 and $3.5 million on Nov. 3, following Alphabet's worst day as a public company. Alphabet's Q3 revenue missed estimates, with search revenue below expectations. ARK also sold shares in Eli Lilly and Amazon, and bought Nurix Therapeutics. Alphabet's stock is down 12.81% since its Oct. 28 close.

Nurix Therapeutics (NASDAQ:NRIX) will present Phase 1a/1b study data for bexobrutideg at the ASH meeting in December 2026. The data shows clinical activity and tolerability at 600 mg daily. The drug is being developed with Roche for treating relapsed/refractory CLL and SLL. Nurix is also conducting multiple clinical trials, including Phase 2 and 3 studies.

ARK ETFs sold $49.2M in SpaceX shares, bought $9M in Nurix Therapeutics. Also sold Alphabet and Eli Lilly, bought Twist Bioscience and Pacific Biosciences. Transactions reflect ARK's strategic shifts in tech and biotech sectors.

Wells Fargo kept Nurix Therapeutics at Equal-Weight but cut its price target to $20 from $25, a 20% reduction. This implies a 22.5% downside from the Nov 3 close of $25.82. Other recent analyst targets for the stock range from $32 to $36.

Sanofi ended a Phase 1 trial of STAT6 degrader SAR448272 and terminated the program, per a Nov. 3, 2026, notice to Nurix Therapeutics. Nurix remains eligible for milestone payments and royalties from other licensed programs under the Sanofi collaboration. Analysts have a Buy rating and $35.00 price target for NRIX, while Spark's AI Analyst rates it Neutral.

Nurix Therapeutics, Inc. (NRIX) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On November 3, 2026, Nurix Therapeutics, Inc. (the “ Company ”) announced that collaboration partner Sanofi S.A. (“ Sanofi ”) had notified the Company of its decision to discontinue the Phase 1 first-in-human clinical trial of SAR448272, an oral STAT6 degr

Ring Christine (Chief Legal Officer) sold 3,957 shares of Nurix Therapeutics, Inc. (NRIX) at $26.28 ($0.10M total) on 2026-10-30.

Insiders at Cue Biopharma (CUE), Nurix Therapeutics (NRIX), Flowers Foods (FLO), MarketAxess (MKTX), and Borr Drilling (BORR) made significant trades. Cue's CEO and other executives sold shares, while Borr Drilling's director made large purchases and sales. These moves may influence investor sentiment.